ADVA
12.3.2020 09:02:07 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched a whole new way for communication service providers (CSPs) to drive more revenue from their already deployed fiber networks. With spectrum as a service , CSPs can now slice the optical spectrum in their fiber infrastructure, just like radio spectrum in 5G networks. They can then sell different frequency blocks to different customers, enabling them to fully harness the untapped value in their networks. Powered by ADVA’s FSP 3000 open line system (OLS), spectrum as a service is an entirely new approach for CSPs to utilize vast amounts of unused spectrum. By leveraging ADVA’s coherent optics, programmable flexgrid technology and intelligent network control, CSPs can start selling fully assured and differentiated optical spectrum services to their customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200312005038/en/
“Today we’re introducing a new way for CSPs to tackle skyrocketing data demand and diminishing margins. Optical spectrum in fiber networks can now be sliced and offered as differentiated services to multiple end users. This gives CSPs a completely fresh business case and a brand new area for revenue growth,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “Our unique open line system is the key to realizing the full benefits of the spectrum-as-a-service approach. Its spectrum gateway functionality and advanced optical layer control empower CSPs to elastically allocate optical spectrum to services and deliver virtually unlimited capacity. What’s more, with optical spectrum services, CSPs can put their end customers in control like never before.”
The ADVA FSP 3000 OLS provides the optimum platform for spectrum-as-a-service offerings. It creates an open and scalable optical layer ready to accommodate evolving demand and the latest innovation. With a modular design as well as multiple multiplexer and amplifier options, it's engineered to meet the specific requirements of modern metro, core and DCI applications. The ADVA FSP 3000 OLS removes the limits of the traditional fixed channel grid systems so that unused spectrum can be put to work. This approach also enables operators to take advantage of flexible resource utilization and future-proof their networks by avoiding unnecessary O/E/O conversions.
“Up until now, CSPs have been unable to monetize the vast amounts of unused spectrum in their networks. But thanks to advances in coherent optics, programmable flexgrid technology and intelligent network control, spectrum as a service is now a real and affordable option. CSPs can use the approach to unleash the full value of their fiber assets,” commented Jörg-Peter Elbers, SVP, advanced technology, ADVA. “Following multiple spectrum-as-a-service proof-of-concepts involving several partners and spanning different network domains, we're now removing the limits on fiber capacity for CSPs across the world. With this launch, we're unlocking the potential of today's fiber infrastructure and ushering in a new age of flexible, future-proof growth.”
Watch this video for more information on ADVA’s spectrum-as-a-service solution: https://youtu.be/FBCuuvYWN4A .
Further details are also available in these slides: https://adva.li/spectrum-as-a-service-slides .
Learn more about ADVA’s FSP 3000 open line system in this video: https://youtu.be/E_P8_ypxR1w .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200312005038/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
